Safety and Efficacy of GW685698X an Inhaled Corticosteroid Once Daily and Twice Daily for the Treatment of Asthma

A Multi-Centre, Randomized, Double Blind Cross-over Study to Assess the Non-inferiority of GW685698X 200mcg Once Daily and 100mcg Twice Daily in Adult and Adolescent Patients With Asthma

The purpose of this study is to compare once and twice daily GW685698 in asthma

Key Inclusion Criteria:

• Clinical diagnosis of Asthma
• Reversibility ≥ 12% and ≥200mls reversibility of FEV1 within approximately 30-minutes following 2 to 4 puffs of albuterol
• FEV1 between 40-85% predicted
• Currently on short acting beta2 agonist therapy

Key Exclusion Criteria:

• History of life threatening asthma
• Respiratory Infection or oropharyngeal candidiasis
• Asthma exacerbation
• Uncontrolled disease or clinical abnormality
• Allergies
• Taking another Investigational medications or other prohibited medications